TECH: Multiomic Expansion And Margin Improvement Will Support Balanced Future Outlook

Analysts have raised their price target on Bio-Techne from approximately 53 dollars to about 60 dollars, citing expectations for modestly faster revenue growth, improving profit margins, and a higher justified future price to earnings multiple.

What's in the News

• Bio-Techne's Lunaphore brand and the Wyss Center for Bio and Neuroengineering in Geneva are collaborating to develop an automated workflow for simultaneous RNA and protein detection in 3D specimens, aiming to extend multiomic spatial biology from 2D into 3D and reduce reliance on animal models (Key Developments).
• The company expanded the launch of its next generation Leo System, adding dual channel fluorescence detection to Simple Western Technology to boost multiplexing, data throughput, and sensitivity for protein analysis, with the ability to process up to 100 capillaries in three hours (Key Developments).
• Bio-Techne and Nucleai reported pivotal SECOMBIT trial data at the SITC 2025 meeting, demonstrating how AI driven spatial biology and a 28 plex mIF panel can predict treatment response and survival in metastatic melanoma across different immunotherapy regimens (Key Developments).
• Bio-Techne introduced the ProximityScope assay for Leica's BOND RX platform, enabling visualization of protein protein interactions with subcellular resolution and integrated RNA protein detection for advanced discovery and translational research (Key Developments).
• The company enhanced its collaboration with Oxford Nanopore Technologies, extending the agreement through 2032 and broadening development of targeted enrichment sequencing kits for screening and diagnosing heritable genetic disorders (Key Developments).

Valuation Changes

• The fair value estimate has risen moderately from approximately 53 dollars to about 60.31 dollars per share, reflecting a higher intrinsic value assessment.
• The discount rate has increased slightly from about 7.29 percent to roughly 7.81 percent, implying a modestly higher required return for investors.
• The revenue growth assumption has risen marginally from roughly 4.84 percent to about 4.97 percent, indicating a slightly more optimistic top line outlook.
• The net profit margin forecast has increased modestly from around 18.39 percent to approximately 19.44 percent, signaling expectations for improved profitability.
• The future P/E multiple has risen meaningfully from about 36.7 times to roughly 41.2 times, suggesting a higher valuation multiple applied to forward earnings.